Drug – bio-affecting and body treating compositions – Preparations characterized by special physical form – Tablets – lozenges – or pills
Patent
1993-07-13
1996-09-17
Venkat, Jyothsna
Drug, bio-affecting and body treating compositions
Preparations characterized by special physical form
Tablets, lozenges, or pills
424464, 424465, A61K 934
Patent
active
055566391
DESCRIPTION:
BRIEF SUMMARY
The present invention relates to a water-dispersible tablet formulation containing a therapeutically active compound.
Therapeutically active compounds or drugs are frequently administered to patients in tablet form where the drug is intended for oral administration since tablets are an especially convenient pharmaceutical form for manufacture, storage and generally usage. However, problems, may arise with the administration of such tablets to patients who have difficulty in swallowing the tablets (for example, children or more seriously ill patients) especially if the tablets are large in size arising from the amount of drug required in each tablet. A solution to such problems is to formulate the tablets in a form whereby they can be dispersed in water to form a dispersion containing the drug which can then be drunk by the patient.
Known water-dispersible tablets include effervescent formulations which rely on the formation of a gas to quickly break up the tablet, but these involve expensive methods of manufacture and strict regulations for such manufacture. Other known water-dispersible tablets use disintegrating agents such as microcrystalline cellulose used in Feldene.RTM. R dispersible tablets. We have tested well-known disintegrating agents (incorporated both internally and externally to the preformed granules) such as sodium starch glycollate (e.g. Explotab), cross-linked povidone (e.g. Kollidon CL) and a cross-linked sodium carboxymethylcellulose (e.g. Ac-Di-Sol) in an acyclovir tablet, but found that they did not provide a satisfactory water-dispersible formulation. We furthermore tested an ion exchange resin (Amberlite 1RP88) as a disintegrating agent and incorporated surface active agents (e.g. sodium lauryl sulphate and sodium docusate) in an attempt to improve tablet wetting and penetrating of water during dispersion, but in all cases the disintegration time was high.
After considerable research and investigation, we have now suprisingly found that the use of a swellable clay within the granulate of a lamotrigine tablet formulation provides a tablet which has good dispersibility in water to provide a dispersion which can be drunk by a patient.
Swellable clays such as Veegum.sup.R and other magnesium aluminium silicates have previously been studied and proposed for use as disintegrating agents, binders and lubricants in the manufacture of tablets, but such studies and proposals were exclusively with respect to tablets intended for swallowing and not for water-dispersible tablets (Rubenstein, Pharmaceutics--The Science of Dosage Form Design (1990) for disintegrants see p 312 and 314). Moreover, there has never been any suggestion that a clay would be suitable to meet the more stringent requirements for dispersible tablets. Tablets for swallowing need only have a disintegration time in water of less 15 minutes and be able to form particles on disintegration in water that can pass through a 2.00 mm mesh aperture (British Pharmacopia test for swallowable tablets). Such long disintegration times and large particle sizes are entirely unsuitable for a dispersible tablet.
Even when swellable clays have been proposed as disintegrating agents for swallowable tablets, they are not regarded as very suitable for such use because their off-white appearance can often discolour the tablet and because they are not as effective as other disintegrating agents (Banker and Anderson--Theory and Practice of Industrial Pharmacy p 328 (1986) and Bhargava et al--Drug Development and Industrial Pharmacy, 17(15), 2093-2102(1991)). In fact, bentonire is identified in Marshall and Rudnic, Modern Pharmaceutics (1990) p 374, as the least swellable of the ten disintegrants listed. There is no mention in the above text-book references of how the swellable clay should be incorporated--i.e. by intra-granular addition or by extra-granular addition. In the former case, the clay would be included in the mixture from which the granulate is formed; in the latter case the clay would be added to the pre-formed granulate. In J. Pharm. Sci
REFERENCES:
patent: 3427379 (1969-02-01), Barry et al.
patent: 3432593 (1969-03-01), Shepard
patent: 3567819 (1971-03-01), Leonia et al.
patent: 4072535 (1978-02-01), Short et al.
patent: 4086335 (1978-04-01), Bruscato et al.
patent: 4159345 (1979-06-01), Takeo et al.
patent: 4209513 (1980-06-01), Torode et al.
patent: 4251518 (1981-02-01), Moore et al.
patent: 4304773 (1981-12-01), Wong et al.
patent: 4305502 (1981-12-01), Gregory et al.
patent: 4322449 (1982-03-01), Voss et al.
patent: 4369308 (1983-01-01), Trubiano
patent: 4371516 (1983-02-01), Gregory et al.
patent: 4414198 (1983-11-01), Michaelson
patent: 4517179 (1985-05-01), Raghunathan
patent: 4600579 (1986-07-01), Salpekar et al.
patent: 4602017 (1986-07-01), Sawyer et al.
patent: 4631305 (1986-12-01), Guyer et al.
patent: 4661521 (1987-04-01), Salpekar et al.
patent: 4711777 (1987-12-01), Tan et al.
patent: 4757090 (1988-07-01), Salpekar et al.
patent: 4774083 (1988-09-01), Tan et al.
patent: 4781925 (1988-11-01), Michelucci et al.
patent: 4832956 (1989-05-01), Gergely et al.
patent: 4837031 (1989-06-01), Denton
patent: 4847249 (1989-07-01), Sawyer et al.
patent: 4904477 (1990-02-01), Ho et al.
patent: 4910023 (1990-03-01), Botzolakis et al.
patent: 4925676 (1990-05-01), Sellassie et al.
patent: 4927639 (1990-05-01), Sellassie et al.
patent: 4950484 (1990-08-01), Olthoff et al.
patent: 4965072 (1990-10-01), Alexander et al.
patent: 4968517 (1990-11-01), Gergely et al.
patent: 4970078 (1990-11-01), Holinej
patent: 4999200 (1991-03-01), Casillan
patent: 5006345 (1991-04-01), Lang
patent: 5037658 (1991-08-01), Urban et al.
patent: 5047247 (1991-09-01), Milovac et al.
patent: 5049586 (1991-09-01), Ortega et al.
patent: 5064656 (1991-11-01), Gergely et al.
patent: 5069910 (1991-12-01), Kovacic et al.
patent: 5073377 (1991-12-01), Alexander et al.
patent: 5085869 (1992-02-01), Olthoff et al.
patent: 5087454 (1992-02-01), Duerholz et al.
patent: 5136080 (1992-08-01), Miller et al.
Thirty-seven Patent Abstracts from World Patents Index (1967-1990) related to Magnesium Aluminum Silicate.
Thirty-six abstracts from chemical Abstracts (1967-present) related to Dispersible Tablet Formulations Based on Veegum-type Magnesium Aluminum Silicate.
Veegum--The Natural Ingredient: R. T. Vanderbilt & Co., p. 9.
Veegum--The Supernatural Ingredient: R. T. Vanderbilt & Co., Booklet (1987).
Veegum--The Versatile Ingredient for Pharmaceutical Formulations: R. T. Vanderbilt & Co., Booklet.
Pharmasorb: Lawrence Industries. pp. 1-10 (1986).
Polargel White Bentonite: American Colloid Co., Booklet.
Mastery in Refinement--Magnabrite & Polargel: American Colloid Co.
Wai, et al., "Applications of the Montmorillonites in Tablet Making," J. Pharm. Sci., 55: 1244-1248 (1966).
Wai & Banker, "Some Physicochemical Properties of the Montmorillonites," J. Pharm. Sci., 55: 1215-1220 (1966).
Granberg, et al., "The Use of the Dried Bentonite as a Disintegrating Agent in Compressed Tablets of Thyroid," J. Am. Pharm. Assoc. Sci., 43: 648-651 (1949).
Gross, et al., "A Comparative Study of Tablet Disintegrating Agents," J. Am. Pharm. Assoc. Sci., 41: 157-161 (1952).
Firouzabadian, et al., "Some Recently Developed Chemicals as Disintegrating Agents for Compressed Tablets," J. Am. Pharm. Assoc. Sci., 43: 248-250 (1954).
Ward, et al., "Evaluation of Tablet Disintegrants," Drug Cosmetic Ind. 91: 35-36, 92, 110-111 (1962).
Nair, et al., "Studies on Disintegration of Compressed Tablets I. Effect on Disintegration of the Procedure Used in Incorporating the Disintegrating Agent," J. Am. Pharm. Assoc. Sci., 46: 131-134 (1957).
Patel, et al., "Veegum as Binding Agent for Compressed Tablets," Indian J. Pharm., 19: 4-10 (1957).
Feinstein, et al., "Comparative Study of Selected Disintegrating Agents," J. Pharm. Sci. 55: 332-334 (1966).
Varley, A., "The Generic Inequivalence of Drugs," JAMA, 206: 1745-1748 (1968).
Delonca, et al., "Study of the Activity of Some Disintegrants as a Function of Procedure and of the Solubility of the Active Principles," J. Pharm.
Brown Donald
Glaxo Wellcome Inc.
Neuner George W.
Venkat Jyothsna
LandOfFree
Water-dispersible tablets does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Water-dispersible tablets, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Water-dispersible tablets will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-411707